Congress trades in Novartis AG (NVS)
5 of the members we track disclosed 10 purchases of NVS between 2022-01-27 and 2026-03-31, and 13 sales. Here is what the stock did afterwards.
Every purchase is measured over the three months after the transaction date, against XLV — the ETF standing in for Healthcare & Pharma — over exactly the same dates. The second figure is the one that carries information: the first mostly reflects what the sector did. How NVS was classified.
How these buys are tagged
Novartis AG is a mega-cap, so a committee-aligned purchase here is tagged Aligned (Mega-cap) rather than Notable: owning a company this size says little about committee access.
| Buys | Number | Return after 3 months | vs. sector | Beat their sector |
|---|---|---|---|---|
| All buys | 10 | +6.4% | +1.3% | 60% |
| Notable (committee-flagged) | 0 | Too few buys to measure | ||
| Unaligned (no committee overlap) | 6 | +9.4% | +5.2% | 83% |
| Cluster, excl. mega-caps | 0 | Too few buys to measure | ||
| Not clustered, excl. mega-caps | 0 | Too few buys to measure | ||
Who bought the most
- Lisa C. McClain — 5 buys
- Alan Armstrong — 2 buys
- Sheldon Whitehouse — 1 buy
- Dan Goldman — 1 buy
- Donald Beyer — 1 buy
Every disclosed purchase
| Member | Bought disclosed |
Signal | Price | 1W | 1M | 3M | vs sector |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | 2026-03-31 2026-07-21 |
Aligned (Mega-cap) | $152.75 | -1.0% | -3.2% | +2.6% | -5.6% |
| Alan Armstrong | 2026-03-30 2026-07-21 |
Aligned (Mega-cap) | $150.36 | +1.6% | -4.9% | +4.8% | -7.0% |
| Lisa C. McClain | 2025-10-30 2025-11-21 |
Unaligned | $122.61 | +3.2% | +6.4% | +21.5% | +14.9% |
| Lisa C. McClain | 2025-09-11 2025-10-22 |
Unaligned | $127.70 | -4.2% | +1.8% | +3.6% | -6.3% |
| Lisa C. McClain | 2025-06-17 2025-08-13 |
Unaligned | $116.41 | +2.1% | -1.6% | +5.5% | +2.9% |
| Lisa C. McClain | 2025-06-11 2025-08-13 |
Unaligned | $118.07 | -1.8% | +2.5% | +7.2% | +6.0% |
| Lisa C. McClain | 2025-06-09 2025-08-13 |
Unaligned | $118.02 | +0.1% | +4.2% | +9.1% | +6.3% |
| Sheldon Whitehouse | 2023-09-20 2023-10-17 |
Aligned (Mega-cap) | $103.58 | -3.2% | -8.6% | -6.2% | -7.1% |
| Dan Goldman | 2023-03-31 2023-04-17 |
Unaligned | $92.00 | +4.6% | +11.5% | +9.7% | +7.2% |
| Donald Beyer | 2022-01-27 2022-02-01 |
Aligned (Mega-cap) | $85.14 | +1.5% | +2.9% | +6.0% | +1.4% |
Prices are the closing price on the transaction date, not what was paid: filings never disclose an execution price. Blank figures mean the window has not elapsed yet. Sales are not scored — a sale closes a position rather than opening one — so the 13 disclosed sales of NVS are not in this table.
Download the data behind this page, or read how every figure is calculated. Trades in NVS are a small part of the full rankings, which score each member across everything they bought.
Data last updated .